Chronic alcohol consumption drives severe liver pathology worldwide. Among these conditions, alcoholic hepatitis represents an acute-on-chronic inflammatory injury associated with substantial morbidity and mortality. Hepatologists continually seek targeted interventions because conventional medical therapies offer limited survival benefits. Emerging evidence highlights immunometabolism as a crucial therapeutic frontier. Specifically, metabolic shifts within hepatic immune cells drive sustained cytokine release and tissue necrosis. Consequently, elucidating how natural bioactive compounds modulate immune cell metabolism could transform clinical management.

Pathophysiological Hallmarks of Alcoholic Hepatitis

Alcoholic liver disease advances through predictable pathological phases. Initial steatosis often progresses to severe steatohepatitis, advanced fibrosis, and irreversible cirrhosis. Sustained ethanol intake disrupts hepatic homeostasis through multiple synergistic pathways. First, ethanol oxidation generates toxic acetaldehyde and excessive reactive oxygen species. These byproducts induce severe oxidative stress within hepatocytes. In addition, chronic alcohol exposure compromises gut mucosal integrity. This bacterial translocation releases lipopolysaccharide into the portal circulation. When bacterial endotoxins reach the hepatic parenchyma, resident Kupffer cells recognize pathogen-associated molecular patterns. Consequently, Kupffer cells trigger intense inflammatory signaling cascades. Pro-inflammatory cytokines, including tumor necrosis factor-alpha and interleukin-1 beta, flood the hepatic microenvironment. This sustained cytokine surge recruits systemic neutrophils and mononuclear cells into the liver parenchyma. Therefore, hepatocellular ballooning, vacuolar degeneration, and microvesicular lipid accumulation accelerate rapidly. Traditional interventions primarily rely on general corticosteroids or supportive abstinence protocols. However, these regimens fail to address the underlying immunometabolic reprogramming that sustains chronic inflammation. Clinicians therefore require precise molecular targets that can halt this progressive inflammatory cascade.

Glycolytic Reprogramming and Kupffer Cell Activation

Immunometabolism dictates how innate immune cells respond to inflammatory triggers. Under quiescent conditions, Kupffer cells rely primarily on mitochondrial oxidative phosphorylation for energy production. However, acute exposure to lipopolysaccharide and interferon-gamma fundamentally alters this metabolic balance. Kupffer cells rapidly undergo metabolic reprogramming toward aerobic glycolysis. This functional shift resembles the Warburg effect typically observed in neoplastic cells. Although aerobic glycolysis yields fewer adenosine triphosphate molecules per glucose molecule, it generates energy rapidly. Furthermore, heightened glycolytic flux provides vital metabolic intermediates for biosynthetic processes. These intermediates fuel the synthesis of inflammatory mediators, chemokines, and reactive oxygen species. Consequently, persistent glycolytic activation locks macrophages into a destructive pro-inflammatory M1 phenotype. This hyperactive state sustains necroinflammation and accelerates hepatocyte death. Conversely, suppressing glycolytic hyperactivation permits immune cells to restore metabolic equilibrium. Thus, targeting the enzymatic regulators of glycolytic flux presents an innovative strategy. Modulating this metabolic checkpoint could silence Kupffer cell hyperreactivity without causing generalized immunosuppression.

The Pivotal Enzymatic Role of PKM2 in Hepatic Inflammation

Pyruvate kinase catalyzes the final rate-limiting step of glycolysis by converting phosphoenolpyruvate into pyruvate. Among its isoforms, pyruvate kinase M2, known as PKM2, uniquely regulates immune cell activation. PKM2 switches between an active tetrameric form and an inactive dimeric conformation. In inflammatory macrophages, dimeric PKM2 accumulates significantly in response to metabolic stress. Importantly, dimeric PKM2 exhibits distinct moonlighting activities beyond standard cytoplasmic glycolysis. It translocates directly into the cell nucleus. Once inside the nucleus, PKM2 acts as a transcriptional co-activator for hypoxia-inducible factor 1-alpha. This molecular interaction directly amplifies the transcription of glycolytic enzymes and pro-inflammatory genes. In addition, nuclear PKM2 facilitates the activation of nuclear factor kappa B signaling. As a result, PKM2 bridges cellular metabolism directly to severe inflammatory signaling. Experimental models of liver injury demonstrate robust upregulation of PKM2 within activated Kupffer cells. Therefore, pharmacological suppression of PKM2 can disrupt this pathogenic feedback loop, dampening both glycolytic flux and destructive inflammatory transcription.

Therapeutic Efficacy and Mechanism of Leonurine

Leonurine is a bioactive alkaloid extracted from the traditional medicinal herb Leonurus japonicus. Researchers have long recognized its potent cardioprotective, antioxidant, and anti-atherosclerotic characteristics. Recent investigations highlight its remarkable capacity to modulate metabolic disorders and suppress inflammatory cascades. Specifically, a groundbreaking study evaluated leonurine in alcohol-induced C57BL/6 mice and lipopolysaccharide-stimulated Kupffer cells. The experimental results demonstrate that leonurine substantially attenuates hepatic damage in vivo. Histological analyses revealed marked reductions in vacuolar degeneration and lipid droplet accumulation within treated liver tissues. Furthermore, leonurine administration normalized elevated serum transaminases and suppressed systemic inflammatory mediators. Mechanistically, leonurine directly engages PKM2, effectively downregulating its protein expression both in vivo and in vitro. By inhibiting PKM2, the compound significantly curtails excess glycolytic flux in stimulated Kupffer cells. Consequently, this intervention halts the pathological glycolytic shift, promoting macrophage reprogramming toward a resolving phenotype. Thus, leonurine confers comprehensive hepatoprotection by simultaneously resolving lipid accumulation and extinguishing macrophage-driven inflammatory responses.

Translational Horizons for Clinical Practice in Hepatology

These preclinical discoveries hold substantial translational significance for managing severe liver disease. Current pharmacological strategies for alcoholic liver damage exhibit significant therapeutic limitations. Corticosteroids often carry risks of severe infection, while nutritional supplementation alone cannot reverse established inflammation. Therefore, developing small molecules that target immunometabolic checkpoints offers immense therapeutic promise. Leonurine represents an attractive therapeutic candidate due to its oral bioavailability and established safety profile. Moreover, targeting PKM2 provides dual benefits: it mitigates abnormal steatosis while attenuating systemic inflammation. Clinicians managing refractory hepatitis may eventually combine metabolic modulators with abstinence support and nutritional therapy. Nevertheless, researchers must complete rigorous pharmacokinetic profiling and multi-center clinical trials in human cohorts. Future investigations must also determine whether leonurine prevents long-term hepatic fibrogenesis and portal hypertension. In summary, deciphering immunometabolic pathways equips clinicians with fresh therapeutic rationales. Targeting PKM2-dependent glycolytic reprogramming clearly marks a promising paradigm shift in modern hepatology.

Frequently Asked Questions

How does PKM2 drive macrophage-mediated liver injury?

Pyruvate kinase M2 serves as a pivotal metabolic switch in hepatic macrophages. When Kupffer cells encounter inflammatory stimuli, PKM2 forms dimers and translocates into the cell nucleus. There, it functions as a transcriptional co-activator for hypoxia-inducible factor 1-alpha, driving the expression of pro-inflammatory cytokines and glycolytic genes. Consequently, PKM2 sustains high glycolytic flux and M1 macrophage polarization, directly worsening hepatocellular injury.

What source provides leonurine and how does it act pharmacologically?

Leonurine is a natural alkaloid isolated from the medicinal plant Leonurus japonicus, commonly known as Chinese motherwort. Pharmacologically, it exhibits potent antioxidant, anti-inflammatory, and metabolic-regulatory properties. In hepatic tissue, leonurine binds and suppresses PKM2 expression. This specific action dampens excessive aerobic glycolysis in activated Kupffer cells. As a result, the alkaloid curtails destructive cytokine production, mitigates vacuolar degeneration, and clears intracellular lipid accumulation.

Can targeting glycolytic reprogramming replace standard treatments for alcoholic hepatitis?

Targeting glycolytic reprogramming represents an emerging experimental strategy rather than an immediate clinical replacement for current therapies. Strict alcohol abstinence, optimal nutritional support, and corticosteroids remain the cornerstones of current management for severe disease. However, conventional options carry notable failure and infection rates. PKM2 inhibitors like leonurine may serve as valuable adjuvant therapies in the future, pending validation in human clinical trials.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Zhang XX et al. Suppression of PKM2 by Leonurine Attenuates Alcoholic Hepatitis Through Regulating Glycolytic Reprogramming. Phytother Res. 2026 Oct 08. doi: 10.1002/ptr.70471. PMID: 42845266.
2. Wu X, Liu X, Chen J, et al. The Hepatoprotective Effect of Leonurine Hydrochloride Against Alcoholic Liver Disease Based on Transcriptomic and Metabolomic Analysis. Front Pharmacol. 2022;13:905202.
3. Inomata Y, Oh JW, Taniguchi K, et al. Downregulation of miR-122-5p Activates Glycolysis via PKM2 in Kupffer Cells of Rat and Mouse Models of Non-Alcoholic Steatohepatitis. Int J Mol Sci. 2022;23(9):5230.
4. Pan CW, Shen JQ, Jin S, et al. Moonlighting Effects of Pyruvate Kinase M2 in Chronic Liver Diseases. Int J Biol Sci. 2023;19(14):4502-4519.